To our knowledge, this is the first study to demonstrate the efficacy of a pharmacological inhibitor of ZDHHC5 in pancreatic cancer, representing a new class of palmitoylated targeted therapies and laying the framework for paradigm-shifting palmitoylated therapy targeting cancer cells. Here, ZDHHC5 is linked to pancreatic neoplasm.